Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices 90709 

requests for similar information 

collections related to these activities. 

As this generic umbrella ICR will 

focus on the awareness, understanding, 

attitudes, preferences, or experiences of 

customers or other stakeholders relating 

to HRSA-funded hotlines, chatlines, or 

portals, the Fast Track Process should 

apply to this information collection. 

Therefore, HRSA also requests OMB 

provide a response on individual 

information collection requests within 

the scope of this generic ICR within 5 

business days. 

Likely Respondents: The most likely 

respondents include users of a HRSAfunded hotline, chatline, or portal. 

These users may include members of 

the public and public or private entities 

who receive HRSA funding. Responses 

to any information collections under 

this generic umbrella ICR are not 

required to obtain or retain any benefit. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose, or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install, and utilize 

technology and systems for the purpose 

of collecting, validating, and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. 

The total annual burden hours 

estimated for this ICR are summarized 

in the table below. HRSA conducted 

this estimate based on reviewing hotline 

and chatline scripts along with online 

portals, in addition to reviewing the 

burden estimates of forms from previous 

HRSA customer service surveys, which 

were approved under other umbrella or 

regular packages. 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Instrument name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Standardized Hotline Interaction .......................................... 100,000 1 100,000 0.17 17,000.00 

Standardized Chatline Interaction ........................................ 100,000 1 100,000 0.17 17,000.00 

Online Portal Submission .................................................... 10,000 1 10,000 0.067 670.00 

Follow-Up Surveys ............................................................... 51,750 1 51,750 0.083 4,295.25 

Total .............................................................................. 261,750 ........................ 261,750 ........................ 38,965.25 

HRSA specifically requests comments 

on: (1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions; (2) the accuracy of the 

estimated burden; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2024–26742 Filed 11–15–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–23– 

137: Science Education Partnership Award 

(SEPA) R25. 

Date: December 11–12, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: James J Li, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 5148, MSC 7849, Bethesda, MD 

20892, 301–806–8065, lijames@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Drug Discovery for Aging, 

Neurodegenerative and Neurological 

Disorders—Panel B. 

Date: December 11, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health 

Rockledge II, 6701 Rockledge Drive Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Kathryn Partlow, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1016D, 

Bethesda, MD 20892 (301) 594–2138 

partlowkc@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Specialized 

Centers of Research Excellence (SCORE) on 

Sex Differences. 

Date: December 11–12, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Elaine Sierra-Rivera, Ph.D. 

IRG Chief Center for Scientific Review 

National Institutes of Health 6701 Rockledge 

Drive, Room 6182 Bethesda, MD 20892 (301) 

435–2514 riverase@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business-Anti-Infective Therapeutics. 

Date: December 11–12, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Marcus Ferrone, PHARMD 

Scientific Review Officer Center for Scientific 

Review National Institutes of Health 6701 

Rockledge Drive Bethesda, MD 20892 (301) 

402–2371 marcus.ferrone@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Molecular Oncology. 

Date: December 11, 2024. 

Time: 11:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 


lotter on DSK11XQN23PROD with NOTICES1
90710 Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices 

Contact Person: Reigh-Yi Lin, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm. 4152, 

MSC 7846, Bethesda, MD 20892, 301–827– 

6009, lin.reigh-yi@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Neurodevelopment, 

Neurodegeneration, and Plasticity. 

Date: December 12, 2024. 

Time: 9:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Robert C Elliott, Ph.D., AB, 

MS Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5190, 

MSC 7846 Bethesda, MD 20892 301–435– 

3009 elliotro@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Member 

Conflict: Auditory, Visual and Cognitive 

Neuroscience. 

Date: December 12, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Alena Valeryevna 

Savonenko, Ph.D. Scientific Review Officer 

Center for Scientific Review National 

Institutes of Health 6701 Rockledge Drive, 

Room 1009J Bethesda, MD 20892 (301) 594– 

3444 savonenkoa2@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Cancer Therapy. 

Date: December 12, 2024. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health 

Rockledge I 6705 Rockledge Drive Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Syed M Quadri, Ph.D., IRG 

Chief, Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 6210, MSC 7804, Bethesda, MD 20892, 

301–435–1211, quadris@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: November 12, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–26757 Filed 11–15–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK U34 

Planning Cooperative Agreement Review 

Meeting. 

Date: February 4, 2025. 

Time: 2:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

NIDDK Democracy II, Suite 7000A 6707 

Democracy Boulevard, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Nisan Bhattacharyya, 

Ph.D., Scientific Review Officer, National 

Institute of Diabetes and Digestive and 

Kidney, National Institute of Health, 6701 

Democracy Boulevard, Suite 668 Bethesda, 

MD 20892, 301–451–2405, 

nisan.bhattacharyya@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: November 12, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–26758 Filed 11–15–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–0166. 

Project: Government Performance and 

Results Act (GPRA) Client/Participant 

Outcomes Measure—(OMB No. 0930– 

0208)—Revision 

SAMHSA is requesting approval for a 

revision of the CSAT Client-level GPRA 

instrument to continue the collection of 

performance and program monitoring 

data of its substance use services grant 

programs. Currently, the information 

collected from this instrument is 

entered and stored in SAMHSA’s 

Performance Accountability and 

Reporting System (SPARS). SPARS is a 

real-time, performance management 

system that captures information on the 

substance use services and mental 

health services delivered through 

SAMHSA’s grant programs across the 

United States. Continued approval of 

this information collection will allow 

SAMHSA to continue to meet 

Government Performance and Results 

Modernization Act of 2010 reporting 

requirements that quantify the effects 

and accomplishments of its 

discretionary grant programs, which are 

consistent with OMB guidance. 

SAMHSA will use the data for annual 

performance reporting required by 

GPRA and comparing baseline with 

discharge and follow-up data. The 

additional information collected 

through this process will allow 

SAMHSA to: (1) report results of these 

performance outcomes; (2) maintain 

consistency with SAMHSA-specific 

performance domains, and (3) assess the 

performance of its discretionary and 

formula grant programs. 

Currently, there are 379,037 total 

burden hours in the OMB-approved 

CSAT Client-level GPRA instrument. 

SAMHSA is now requesting an increase 

to 631,682 burden hours. The increase 

of 252,645 burden hours is due to the 

following: 

• Additional time allocated for 

interviews, but also improved estimates 


lotter on DSK11XQN23PROD with NOTICES1